An interventional study of Interactive Virtual Reality and Passive Virtual Reality in Heart Surgery, Thoracic Surgery and Opioid, sponsored by Filomena R B G Galas. Recruiting at 1 site in Brazil. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Filomena R B G Galas · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 211 studies in Pain with a site in Brazil — 19 open to participants now, 21 under way, 1 of them phase 3. Pain · Brazil.
Among the 211 studies in Pain with a site in Brazil, this one is the 93rd largest by planned enrollment of the 204 interventional ones that give a count, is one of 12 that started in 2024, is one of 127 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 203rd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →19 of the 211 studies in Pain with a site in Brazil are open now. Recruiting first, the newest first:
University of Brasilia · Sites in Brazil
Ages 18–60
Faculdade de Ciências Médicas de Minas Gerais · Sites in Brazil
Ages 18–65 · Healthy volunteers
University of Nove de Julho · Sites in Brazil
Ages 18–65
Universidade Federal de Pernambuco · Sites in Brazil
Ages 18+
University of Sao Paulo · Sites in Brazil
Ages 50–80
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
211 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 25 · Phase 4 29
First in 2004; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 60 across the 204 interventional studies, 100 across the 7 observational. Of the 136 that completed or were terminated, 12 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 211 have an industry lead sponsor. The 10 most frequent:
Filomena R B G Galas is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Filomena R B G Galas has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
5 of the studies in Pain with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07552974Phase 3Associação Pan-Americana Multidisciplinar de EndocanabinologiaCBD Supplementation in Brazilian Jiu-Jitsu Athletes | 2027-02-01 |
| NCT07569276Universidade Federal do ParaEffects of an Experimental Propolis Gel on Tooth Sensitivity Control and Post-bleaching Color Change: a Randomized Clinical Trial | 2026-12-30 |
| NCT06460415Federal University of Health Science of Porto AlegreEffects of Photobiomodulation on Pain and Sexual Function in Women With Dyspareunia: Randomized Clinical Trial | 2027-01 |
| NCT07599514Universidade Federal do ParaEfficacy of an Experimental Gel Based on Libidibia Ferrea on Post-bleaching Tooth Sensitivity | 2027-01-30 |
| NCT06984796University of Nove de JulhoPhotobiomodulation on Pain Perception During the Insertion of the T 380 Copper Intrauterine Device (IUD) | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 211 studies in Pain with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to evaluate the efficacy of virtual reality (VR) as an adjunctive therapeutic method to reduce opioid consumption during the postoperative period of cardiac and thoracic surgeries. Conducted at InCor/HCFMUSP, this single-center, prospective, randomized trial will include 60 patients aged 16 to 40 undergoing procedures such as valve replacements, pulmonary decortication, and video-assisted thoracic surgeries.
Patients will be randomized into three groups. The Interactive VR group receives standard anesthesia protocol combined with interactive VR therapy using games and immersive environments. The Passive VR group receives standard protocol combined with passive 360-degree immersive videos. The Control group receives standard anesthesia protocol without VR intervention. The intervention occurs in three daily sessions lasting 30-45 minutes each over the first five postoperative days or until hospital discharge.
The primary objective is to measure the reduction in total opioid consumption through medical prescriptions and patient-controlled analgesia (PCA) pump usage. Secondary objectives include pain intensity assessed by the Visual Analogue Scale (VAS), incidence of postoperative nausea and vomiting (PONV), duration of mechanical and non-invasive ventilation, length of stay in the ICU and hospital, occurrence of paralytic ileus, patient satisfaction, and cognitive status using the Mini-Mental State Examination (MMSE).
Opioids are standard for postoperative pain but are associated with adverse effects like respiratory depression. VR offers an innovative approach by creating immersive environments that serve as cognitive distractions to modulate pain perception and reduce anxiety. The study anticipates that VR will enhance pain control and improve recovery metrics, serving as a safe and scalable complement to traditional postoperative management.
Postoperative pain management in major cardiac and thoracic surgeries remains a significant clinical challenge due to the side-effect profile of opioids, including respiratory depression and dependency. This study explores Virtual Reality (VR) as a non-pharmacological adjunct based on the gate control theory and the concept of immersive distraction. By engaging multiple sensory faculties, VR aims to compete with nociceptive stimuli for limited attentional resources, thereby modulating pain perception and reducing the emotional component of the pain experience.
This clinical trial compares two distinct VR modalities to identify the most effective mechanism for pain modulation in a high-complexity surgical setting. The Interactive VR arm utilizes high-fidelity devices to engage patients in tasks requiring motor coordination and active cognitive processing, such as interactive gaming. This level of engagement is hypothesized to induce a deeper state of presence. The Passive VR arm focuses on contemplative, 360-degree immersive environments designed to induce physiological relaxation and calmness through visual immersion in tranquil natural settings.
The intervention protocol is standardized to begin on the first postoperative day at the Heart Institute (InCor). Each session is supervised by the research team to ensure proper equipment usage and to monitor for potential adverse effects, such as cybersickness or spatial disorientation. By comparing these immersive levels against a control group receiving standard institutional care, the study seeks to quantify the opioid-sparing effect of digital therapeutics. Statistical analysis will utilize multivariate models to identify associations between VR exposure and improved recovery indicators, providing evidence for the integration of VR into multimodal analgesia strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Arm 1 will receive standard postoperative care plus virtual reality (VR) therapy using both interactive games and passive imagery. The goal is to reduce opioid consumption and improve recovery through immersive distraction. VR sessions will be held three times daily, lasting 30-45 minutes each, for five consecutive postoperative days or until discharge. Games such as Fruit Ninja 2, Beat Saber, and Oculus First Contact offer stimulating experiences, while passive content from YouTube VR provides relaxing visual environments. Patients will be trained to operate the VR device and choose content based on their preference. All sessions will be supervised by the study team to ensure proper use and maximize therapeutic effect.
Device: Interactive Virtual Reality
Participants in Arm 2 will receive standard postoperative care plus virtual reality (VR) therapy focused solely on passive imagery for distraction. VR sessions will occur three times daily, each lasting 30-45 minutes, for five consecutive postoperative days or until discharge. Patients will view calming, immersive content-such as nature scenes and relaxing landscapes-available on platforms like YouTube VR. These experiences aim to reduce opioid consumption and improve recovery by decreasing pain perception. Participants will be trained to use the device and guided by the study team, who will supervise each session to ensure proper use and maximize therapeutic effect.
Device: Passive Virtual Reality
Participants in Arm 3 will serve as the control group, receiving standard postoperative care without virtual reality (VR) intervention. Standard care includes institutional pain management protocols, such as the use of opioids and non-opioid analgesics after cardiac or thoracic surgery. No immersive or distraction-based technologies will be provided. This group serves as a baseline for comparison with the VR groups (Groups 1 and 2), enabling evaluation of the impact of VR on opioid consumption, pain perception, and recovery outcomes. Data from Group 3 will help assess the added value of VR as a complementary tool in postoperative care.
Patients will utilize the Meta Quest 2 headset to engage in interactive applications requiring motor and cognitive tasks, such as Fruit Ninja 2 and Beat Saber, along with passive immersive software like Youtube VR. This dual approach combined with the institutional anesthesia protocol aims to maximize cognitive distraction. The intervention consists of three daily sessions of 30 to 45 minutes for five days postoperatively.
Patients in the Passive VR arm will receive standard anesthesia protocol combined with passive Virtual Reality (VR) therapy. This involves the use of a VR headset to watch immersive 360-degree videos, such as tranquil natural landscapes or underwater scenes, designed to promote relaxation and reduce anxiety. The VR sessions do not require active participation, allowing patients to passively observe calming environments. The intervention will be administered for 3 sessions per day, lasting 30-45 minutes each, over 5 consecutive postoperative days.
Reduction in Opioid Consumption
Measured by the total dose of opioids administered postoperatively, converted to Morphine Milligram Equivalents (MME), over the first 5 days.
Time frame: From the end of surgery up to 5 days after surgery
Occurrence of Nausea and Vomiting
Frequency of postoperative nausea and vomiting episodes
Time frame: Within 5 days after surgery
Length of ICU Stay
Number of days spent in the ICU
Time frame: Within 5 days after surgery
Length of Hospital Stay
Number of days hospitalized
Time frame: Within 30 days after surgery
Length of Mechanical Ventilation
Hours of mechanical ventilation
Time frame: Within 5 days after surgery
Length of Non-Invasive Ventilation
Hours of non-invasive ventilation
Time frame: Within 5 days after surgery
Occurrence of Paralytic Ileus
Presence of paralytic ileus postoperatively
Time frame: Within 5 days after surgery
Patient Satisfaction
Patient satisfaction will be assessed using a Likert scale ranging from 1 to 5, where 1 indicates "very dissatisfied" and 5 indicates "very satisfied". Higher scores represent a better outcome (greater satisfaction).
Time frame: Within 5 days after surgery
Postoperative Pain
Pain intensity will be measured using the Visual Analog Scale (VAS), which ranges from 0 to 10. A score of 0 represents "no pain" and 10 represents the "worst pain imaginable". Higher scores represent a worse outcome (greater pain intensity).
Time frame: Within 5 days after surgery
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for May 2026, 17 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 17 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Filomena R B G Galas